multiQure™ is a life sciences company committed to developing therapies for rare genetic neurodegenerative disorders. Our most advanced therapeutic candidate is for Huntington's disease (HD).

Nationale Nederlanden PTE – the largest institutional investor in the CEE region, joins the shareholder base of multiQure

Esaliens TFI – one of the leading independent institutional investors in Poland, joins the shareholder base of multiQure

Pure Biologics has changed its name to multiQure and completed the transformation of its business model

Changes to the governing bodies of the future multiQure Company reflecting its business transformation

Nationale Nederlanden PTE – the largest institutional investor in the CEE region, joins the shareholder base of multiQure

Esaliens TFI – one of the leading independent institutional investors in Poland, joins the shareholder base of multiQure

Pure Biologics has changed its name to multiQure and completed the transformation of its business model

Changes to the governing bodies of the future multiQure Company reflecting its business transformation

Therapeutic portfolio

multiQure's therapeutic portfolio comprises RNAi gene therapy, primarily targeting Huntington's disease, but also other polyglutamine diseases. Our therapy is a best-in-class solution which, unlike the therapies commonly available on the market, halts the progression of the disease rather than merely alleviating its symptoms. Our portfolio also includes immuno-oncology projects.

RNAi Technology Immuno-oncology therapies

Investors & media

multiQure is the first listed company in Poland to pursue the American biotech model. Our goal is to confirm the efficacy of our RNAi therapy in patients, and its safety profile, as quickly as possible, in order to give investors and potential partners a clear answer rather than promises.